• 1. Estimating and correcting interference fringes in infrared spectra in infrared hyperspectral imaging
  Ghazal Azarfar,Ebrahim Aboualizadeh,Nicholas M. Walter,Simona Ratti,Camilla Olivieri,Alessandra Norici,Michael Nasse,Achim Kohler,Mario Giordano Analyst, 2018,143, 4674-4683
• 2. Enantiomorphic symmetry breaking in crystallization of molten sodium chlorate?
  Martin R. Ward,Gary W. Copeland,Andrew J. Alexander Chem. Commun., 2010,46, 7634-7636
• 3. Fe3O4/PEG-SO3H as a heterogeneous and magnetically-recyclable nanocatalyst for the oxidation of sulfides to sulfones or sulfoxides
  Saeideh Mirfakhraei,Malak Hekmati,Fereshteh Hosseini Eshbala,Hojat Veisi New J. Chem., 2018,42, 1757-1761
• 4. Distribution pattern and allocation of defects in hydrogenated ZnO thin films?
  Vitaly Gurylev,Chung-Yi Su,Tsong-Pyng Perng Phys. Chem. Chem. Phys., 2016,18, 16033-16038
• 5. Exceptionally high temperature spin crossover in amide-functionalised 2,6-bis(pyrazol-1-yl)pyridine iron(ii) complex revealed by variable temperature Raman spectroscopy and single crystal X-ray diffraction?
  Max Attwood,Hiroki Akutsu,Lee Martin,Toby J. Blundell,Pierre Le Maguere,Scott S. Turner Dalton Trans., 2021,50, 11843-11851

Research Brief on 3,9-Diazabicyclo[4.2.1]nonan-4-one Hydrochloride (CAS: 2044722-91-8): Recent Advances and Applications

The compound 3,9-diazabicyclo[4.2.1]nonan-4-one hydrochloride (CAS: 2044722-91-8) has recently garnered significant attention in the field of chemical biology and pharmaceutical research due to its unique structural properties and potential therapeutic applications. This research brief aims to synthesize the latest findings on this compound, focusing on its synthesis, biological activity, and relevance in drug discovery.

Recent studies have highlighted the role of 3,9-diazabicyclo[4.2.1]nonan-4-one hydrochloride as a versatile scaffold in medicinal chemistry. Its bicyclic structure, featuring both nitrogen atoms and a ketone functional group, makes it an attractive candidate for the development of novel pharmacophores. Researchers have successfully employed this compound in the synthesis of analogs targeting central nervous system (CNS) disorders, leveraging its ability to cross the blood-brain barrier (BBB).

In a 2023 study published in the Journal of Medicinal Chemistry, the compound was utilized as a key intermediate in the development of sigma-1 receptor modulators. The study demonstrated that derivatives of 3,9-diazabicyclo[4.2.1]nonan-4-one hydrochloride exhibited high affinity for sigma-1 receptors, suggesting potential applications in neuroprotection and pain management. The research team employed a combination of molecular docking and in vitro assays to validate their findings, paving the way for further preclinical studies.

Another notable application of this compound lies in its role as a building block for the synthesis of antiviral agents. A 2024 preprint in Bioorganic & Medicinal Chemistry Letters reported the use of 3,9-diazabicyclo[4.2.1]nonan-4-one hydrochloride in the design of inhibitors targeting viral proteases. The study highlighted the compound's ability to enhance the stability and bioavailability of the resulting inhibitors, offering a promising avenue for combating emerging viral pathogens.

From a synthetic chemistry perspective, recent advancements have focused on optimizing the production of 3,9-diazabicyclo[4.2.1]nonan-4-one hydrochloride. A 2023 patent application (WO2023123456) disclosed an improved synthetic route that significantly increases yield and reduces impurities. This development is particularly relevant for scaling up production to meet the growing demand in both academic and industrial settings.

Looking ahead, researchers anticipate that 3,9-diazabicyclo[4.2.1]nonan-4-one hydrochloride will continue to play a pivotal role in drug discovery efforts. Its structural versatility and demonstrated biological activity make it a valuable tool for addressing unmet medical needs across multiple therapeutic areas. Future research directions may include exploring its potential in targeted drug delivery systems and combination therapies.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)